ArticleBMC cancer2026
Clinicopathological and molecular characterization of tumor-associated macrophages in sporadic and Xeroderma Pigmentosum-related cutaneous melanoma.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundXeroderma pigmentosum (XP) is a rare autosomal recessive disorder, resulting from genetic defects in the nucleotide excision repair (NER) pathway. It predisposes individuals to skin cancers, including melanoma. The melanoma microenvironment is enriched with inflammatory mediators, particularly macrophages, which may serve as prognostic biomarkers or therapeutic targets. While inflammation is linked to melanoma outcomes, its role in carcinogenesis among XP patients remains poorly understood.
methodsWe assessed the cytokine profiles in the sera of XP-melanoma patients, as well as the expression level of a pan-macrophage marker (CD68), M2-markers CD163, and M1-associated nitric oxide synthase (iNOS) expression.
resultsXP patients exhibited significantly reduced levels of iNOS, MIP-1β, MCP-1, and IL-33, indicating an impaired inflammatory and macrophage-mediated immune response. We also found that IL-33 and iNOS levels were positively correlated with the density of inflammatory infiltrates. Moreover, in vitro assays using G361 melanoma cells demonstrated that both pro-inflammatory macrophage-conditioned media and exogenous IL-33 suppressed tumor cell proliferation.
conclusionThis study emphasizes the need for specific macrophage biomarkers and proposes local interleukin-33 delivery as a potential therapy for poorly infiltrated melanoma. This also suggests that NER-deficient patients may exhibit unique molecular profiles, warranting personalized treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.